Zobrazeno 1 - 10
of 23
pro vyhledávání: '"P G, Sleph"'
Autor:
K S, Atwal, G J, Grover, S Z, Ahmed, F N, Ferrara, T W, Harper, K S, Kim, P G, Sleph, S, Dzwonczyk, A D, Russell, S, Moreland
Publikováno v:
Journal of Medicinal Chemistry. 36:3971-3974
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e5171cdb47970990fb3009d55c220f
https://doi.org/10.1021/jm00076a027
https://doi.org/10.1021/jm00076a027
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 280(2)
There has been controversy regarding whether ATP-sensitive potassium channel activation protects hearts through adenosine A1 receptor activation or the converse. We addressed this issue by determining the effect of the adenosine A1 receptor antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3a4368849b18fa652c50594e458527e
https://pubmed.ncbi.nlm.nih.gov/9023261
https://pubmed.ncbi.nlm.nih.gov/9023261
Publikováno v:
Cardiovascular research. 31(4)
An interaction between adenosine A1 receptors and ATP-sensitive potassium channels (KATP) has been hypothesized to mediate preconditioning in several species. Unlike other species tested, KATP blockers and A1 antagonists do not abolish preconditionin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e499db1c88b89e9cd6a6e256e6a93499
https://pubmed.ncbi.nlm.nih.gov/8689642
https://pubmed.ncbi.nlm.nih.gov/8689642
Publikováno v:
Cardiovascular research. 30(5)
We determine if action potential duration (APD) shortening and cardioprotection are separable phenomena in ATP-sensitive potassium channel (KATP) openers which protect ischemic myocardium via a glyburide-reversible mechanism.We determined the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dafc362604e306584284028669885a70
https://pubmed.ncbi.nlm.nih.gov/8595620
https://pubmed.ncbi.nlm.nih.gov/8595620
Autor:
G J, Grover, S, Dzwonczyk, D M, McMullen, D E, Normandin, C S, Parham, P G, Sleph, S, Moreland
Publikováno v:
Journal of cardiovascular pharmacology. 26(2)
SQ 32,926 and SQ 32,547, two dihydropyrimidine calcium channel blockers, were characterized as potent inhibitors of depolarization-induced contractions of isolated smooth muscle preparations. In rat aorta, the IC50 values were 5.5 nM for SQ 32,547 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dff737d56077543e113639c4c7a5f9f4
https://pubmed.ncbi.nlm.nih.gov/7475054
https://pubmed.ncbi.nlm.nih.gov/7475054
Publikováno v:
Cardiovascular research. 29(1)
The mechanism of the protective effect of ischaemic preconditioning in the myocardium is not yet known. The aim of this study was to test the hypothesis that endogenous myocardial catecholamines may be mediators of preconditioning.To test whether end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::43fdc19a8fd3195d940b4d9c9fc6881e
https://pubmed.ncbi.nlm.nih.gov/7895230
https://pubmed.ncbi.nlm.nih.gov/7895230
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 269(2)
Recent published studies indicate that the cyclooxygenase inhibitor meclofenamate can abolish preconditioning. Unpublished preliminary data from this laboratory suggest that meclofenamate may be blocking cardiac ATP-sensitive potassium channels (KATP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8aed100bd91053d4da6e248c887274b5
https://pubmed.ncbi.nlm.nih.gov/8182522
https://pubmed.ncbi.nlm.nih.gov/8182522
Autor:
G J, Grover, P G, Sleph
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 268(1)
The goal of this study was to determine the cardioprotective profile for the nucleoside transport inhibitor 2-(aminocarboxyl)-N-(4-amino-2,6-dichlorophenyl)-4-[5,5-bis(4- fluorophenyl)pentyl]-1-piperazinylacetamide trihydrochloride-2,5 hydrate (R 752
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6514eb8849856899629d11a50fd26d2e
https://pubmed.ncbi.nlm.nih.gov/8301599
https://pubmed.ncbi.nlm.nih.gov/8301599
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 267(1)
A novel pyranoquinoline analog (BMS-188107) of the ATP-sensitive potassium channel (KATP) opener cromakalim was previously shown to be devoid of KATP opening activity in nonischemic myocardium and vascular smooth muscle, but appeared to be a relative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f9a018fcfc9ce08192d4202003df5823
https://pubmed.ncbi.nlm.nih.gov/8229736
https://pubmed.ncbi.nlm.nih.gov/8229736
Autor:
C A, Sargent, P G, Sleph, S, Dzwonczyk, M A, Smith, D, Normandin, M J, Antonaccio, G J, Grover
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 265(2)
The SH-containing angiotensin-converting enzyme (ACE) inhibitors zofenopril and captopril have been shown to protect the ischemic myocardium independently of ACE inhibition. Zofenopril (30-100 microM) enhanced reperfusion contractile function and red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1cdf525dc9b2b625c78c61410d15581c
https://pubmed.ncbi.nlm.nih.gov/8496812
https://pubmed.ncbi.nlm.nih.gov/8496812